结直肠癌患者采用奥沙利铂结合卡培他滨治疗的效果分析

Therapeutic Effect of Oxaliplatin Combined with Capecitabine in Patients with Colorectal Cancer

目的 分析结直肠癌治疗中采用奥沙利铂联合卡培他滨的价值。方法 选取2022年8月—2024年1月苏州市立医院收治的185例结直肠癌患者为研究对象,根据随机数表法分为对照组(92例,卡培他滨治疗)、观察组(92例,奥沙利铂联合卡培他滨治疗)。比较两组临床疗效、免疫功能、生物学行为指标、肿瘤标志物。结果 观察组临床疗效(67.74%)高于对照组(52.17%),差异有统计学意义(χ^(2)=4.043,P<0.05)。观察组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)高于对照组,差异有统计学意义(P均<0.05)。观察组胶原三股螺旋重复蛋白1、成蛋白样3型蛋白、存活蛋白水平低于对照组,差异有统计学意义(P均<0.05)。观察组癌胚抗原、糖类抗原199水平低于对照组,差异有统计学意义(P均<0.05)。结论 奥沙利铂联合卡培他滨可以显著改善结肠癌患者的免疫功能和肿瘤标志物水平。

Objective To analyze the value of combining oxaliplatin and capecitabine in the treatment of colorectal cancer.Methods A total of 185 colorectal cancer patients admitted to Suzhou Municipal Hospital from August 2022 to January 2024 were selected as the study subjects,which were divided into control group(92 cases treated with capecitabine) and observation group (93 cases treated with oxaliplatin and capecitabine).The clinical efficacy,immune function,biological behavioral indicators,and tumor markers were compared between the two groups.Results The clinical efficacy of the observation group (67.74%) was higher than that of the control group (52.17%),and the difference was statistically significant (χ^(2)=4.043,P<0.05);CD3^(+),CD4^(+),CD4^(+)/CD8^(+)of the observation group were higher than that of the observation group,and the differences were statistically significant (all P<0.05).The levels of Collagen triple helix repeat protein 1,protein-like type 3 protein and survival protein in observation group were lower than those in control group,and the differences were statistically significant (all P<0.05).The levels of carcinoembryonic antigen and carbohydrate antigen 199 in observation group were lower than those in control group,and the differences were statistically significant (both P<0.05).Conclusion Oxaliplatin-capecitabine combination significantly improves the immune function and tumor marker level in colon cancer patients,and can reduce other medical costs.